CHICAGO – Clovis Oncology Inc. took a big step ahead in preparations for filing its new drug application (NDA) for the experimental non-small-cell lung cancer (NSCLC) therapy, rociletinib, showcasing data from an ongoing phase II study testing the drug in a group of heavily pre-treated patients, most of whom had developed resistance to current treatments.